Approved for Ibandronate sodium is a bisphosphonate indicated for the treatment and prevention of postmenopausal osteoporosis. ( 1.1 ) Limitations of Use The optimal duration of use has not been determined. For patients at low -risk for fracture, consider drug discontinuation after 3 to 5 years of use. ( 1.2 ). The action of ibandronate on bone tissue is based on its affinity for hydroxyapatite,…
Loading full data from Know Your Drugs Institute…